Protection offered by COVID-19 vaccine against morbidity and mortality due to COVID-19 infection: a postvaccination cohort study

Authors

  • Arti Muley Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Sona Mitra Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Ashish Bavishi Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Hema Bhojani Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Geetika Patel Department of Community Medicine, PIMSR, Parul University, Gujarat, India
  • Dinesh Nakum Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Sakshi Shah Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Pratham Prajapati Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Ayush Abraham Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Parth Patel Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Mit Patel Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Stavan Padia Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Preyasi Chaudhari Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Aayushi Gadhvi Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Gehna Patel Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Jeel Dhapa Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Shifa Gajdhar Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Chitrali . Department of Medicine, PIMSR, Parul University, Gujarat, India
  • Nikunj Bhingadriya Department of Medicine, PIMSR, Parul University, Gujarat, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20214520

Keywords:

COVID 19 vaccine, Morbidity, Mortality

Abstract

Background: Many vaccines have been developed, approved and administered against the COVID-19. Phase 2 and 3 trials have proved the safety and tolerability of these. This study was conducted to assess effect of the vaccines on morbidity and mortality due to postvaccination new COVID-19 infection.

Methods: This was an observational, retrospective cohort study. The patients admitted with COVID-19 from 1st April 2021 till 30th April 2021 who were willing to participate were included. All the patients were telephonically contacted post discharge and enquired regarding history of vaccination, events during hospitalization and outcome. The data so collected was analysed to compare the morbidity (oxygen requirement, need of ICU admission and need of BiPAP or invasive ventilation) and mortality between vaccinated and nonvaccinated COVID-19 patients and relation of time elapsed post vaccination with morbidity and mortality.

Results: Total 431 patients were included. There was significant difference between the two groups in terms of need for ICU admission (OR 0.503; CI 0.30-0.82, p=0.008) as well as requirement of BiPAP or invasive ventilation (OR 0.57; CI 0.33-0.98, p=0.05). Mortality was significantly less in the vaccinated group; OR 0.48 (0.24-0.95), p=0.04). Ten patients had received both doses. Only one required ICU while none of them required invasive ventilation and none expired.

Conclusions: COVID-19 vaccine gives significant protection against COVID-19 infection related ICU admission, need of mechanical ventilation and mortality even after single dose. Two doses of vaccine may afford better protection against the disease.

Author Biographies

Ayush Abraham, Department of Medicine, PIMSR, Parul University, Gujarat, India

Student, Parul Institute of Medical Sciences & Research, Parul University

Preyasi Chaudhari, Department of Medicine, PIMSR, Parul University, Gujarat, India

References

Walker PGT, Whittaker C, Watson OJ. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science. 2020;369:413-22.

Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020;580:576-7.

Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516-27.

Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science. 2020;368:948-50.

Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368:945-6.

US Department of Health and Human Services: Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19: guidance for industry. June, 2020. Available at: https://www.fda.gov/ media/139638/download. Accessed on 10 Jan. 20201.

WHO. R and D blueprint: an international randomized trial of candidate vaccines against COVID-19. Geneva: World Health Organization. 2020. Available at: https://www.who.int/publications/i/item/an-international-randomised-trial-of-candidate-vaccines-against-covid-19.

Zhang Y, Zeng G, Pan H. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181-92.

Maheshi N Ramasamy, Angela M Minassian, Katie J Ewer. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979-93.

Voysey M, Clemens SAC, Madhi SA. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.

Zhu FC, Guan XH, Li YH, Huang JY, Jiang T. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020, 396, 479−488.

Ramasamy MN, Minassian AM, Ewer KJ. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2020;396(10267):1979-93.

Downloads

Published

2021-11-23

Issue

Section

Original Research Articles